biotech · Advanced Solid Tumor · Sjogren's Disease · CGEM
Cullinan Therapeutics
Octagon Therapeutics is a biotech organization headquartered in Providence, USA. It trades on NYSE under ticker CGEM. Primary therapeutic focus areas include Advanced Solid Tumor, Sjogren's Disease, Acute Myeloid Leukemi
Company details
- Status
- Public
- HQ
- Dyer St, Providence, Rhode Island 02903, US
- Founded
- 2017
- Employees
- 7
- Programs
- 16
- Drugs
- 14
- Patents
- 3
CLN-619-001
Phase 1 · other · Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer
CLN-619-001 for Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer is a Phase 1 program (other) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CLN-619-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cullinan Therapeutics
- Phase
- Phase 1
- Modality
- other
- Indication
- Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer
- Status
- active
- Trials
- 1